Short Interest in Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Increases By 161.1%

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) saw a significant increase in short interest in June. As of June 15th, there was short interest totaling 1,343,395 shares, an increase of 161.1% from the May 31st total of 514,441 shares. Based on an average daily trading volume, of 282,980 shares, the short-interest ratio is presently 4.7 days. Currently, 2.8% of the company’s stock are short sold.

Odyssey Therapeutics Price Performance

Shares of Odyssey Therapeutics stock opened at $18.06 on Monday. Odyssey Therapeutics has a fifty-two week low of $15.35 and a fifty-two week high of $20.30.

Odyssey Therapeutics (NASDAQ:ODTX) last posted its quarterly earnings data on Wednesday, June 17th. The company reported $999.00 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.31) by $1,000.31.

Insider Buying and Selling

In related news, Director Nan (Ln) Li acquired 1,111,111 shares of the stock in a transaction dated Monday, May 11th. The shares were acquired at an average price of $18.00 per share, with a total value of $19,999,998.00. Following the acquisition, the director owned 3,333,516 shares in the company, valued at approximately $60,003,288. The trade was a 50.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Sr One Capital Management, Llc sold 1,780 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $18.00, for a total value of $32,040.00. Following the completion of the transaction, the insider directly owned 440,981 shares in the company, valued at $7,937,658. The trade was a 0.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have acquired 4,183,777 shares of company stock valued at $75,319,986.

Analysts Set New Price Targets

ODTX has been the subject of a number of recent analyst reports. TD Cowen assumed coverage on Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set a “buy” rating for the company. Zacks Research upgraded shares of Odyssey Therapeutics to a “hold” rating in a research note on Wednesday, June 3rd. Wedbush began coverage on shares of Odyssey Therapeutics in a report on Tuesday, June 2nd. They set an “outperform” rating and a $30.00 price objective for the company. JPMorgan Chase & Co. began coverage on shares of Odyssey Therapeutics in a report on Tuesday, June 2nd. They set an “overweight” rating and a $26.00 price objective for the company. Finally, Cantor Fitzgerald began coverage on shares of Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued an “overweight” rating on the stock. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $32.00.